Literature DB >> 27784062

Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity.

Matthew J Klebanoff1, Jagpreet Chhatwal2, Jacob D Nudel3, Kathleen E Corey4, Lee M Kaplan4, Chin Hur2.   

Abstract

Importance: Severe obesity affects 4% to 6% of US youth and is increasing in prevalence. Bariatric surgery for the treatment of adolescents with severe obesity is becoming more common, but data on cost-effectiveness are limited. Objective: To assess the cost-effectiveness of bariatric surgery for adolescents with obesity using recently published results from the Teen-Longitudinal Assessment of Bariatric Surgery study. Design, Setting, and Patients: A state-transition model was constructed to compare 2 strategies: no surgery and bariatric surgery. In the no surgery strategy, patients remained at their initial body mass index (calculated as weight in kilograms divided by height in meters squared) over time. In the bariatric surgery strategy, patients were subjected to risks of perioperative mortality and complications as well as initial morbidity but also experienced longer-term quality-of-life improvements associated with weight loss. Cohort demographic information-of the 228 patients included, the mean (SD) age was 17 (1.6) years, the mean (range) body mass index was 53 (34-88), and 171 (75.0%) were female-surgery-related outcomes, and base case time horizon (3 years) were based on data from the Teen-Longitudinal Assessment of Bariatric Surgery study. One-way and probabilistic sensitivity analyses were performed. Main Outcomes and Measures: Quality-adjusted life-years (QALYs), total costs (in US dollars adjusted to 2015-year values using the Consumer Price Index), and incremental cost-effectiveness ratios (ICERs). A willingness-to-pay threshold of $100 000 per QALY was used to assess cost-effectiveness.
Results: After 3 years, surgery led to a gain of 0.199 QALYs compared with no surgery at an incremental cost of $30 747, yielding an unfavorable ICER of $154 684 per QALY. When the clinical study results were extrapolated to 4 years, the ICER decreased to $114 078 per QALY and became cost-effective by 5 years with an ICER of $91 032 per QALY. Outcomes were robust in most 1-way and probabilistic sensitivity analyses. Conclusions and Relevance: Bariatric surgery incurs substantial initial cost and morbidity. We found that surgery could be a cost-effective treatment for adolescents with severe obesity if assessed over a time horizon of 5 years. Our study underscores the need for long-term clinical trials in adolescents with at least 5 years of follow-up data that capture financial and quality-of-life end points.

Entities:  

Mesh:

Year:  2017        PMID: 27784062     DOI: 10.1001/jamasurg.2016.3640

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  24 in total

1.  Evaluation of the Trends, Characteristics, and Outcomes in North American Youth Undergoing Elective Bariatric Surgery.

Authors:  Valentin Mocanu; Krista Lai; Jerry T Dang; Noah J Switzer; Daniel W Birch; Geoff D C Ball; Shahzeer Karmali
Journal:  Obes Surg       Date:  2021-02-06       Impact factor: 4.129

2.  Impact of Bariatric Surgery on Outcomes of Patients with Sickle Cell Disease: a Nationwide Inpatient Sample Analysis, 2004-2014.

Authors:  Prabin Sharma; Thomas R McCarty; Siddhartha Yadav; Julius N Ngu; Basile Njei
Journal:  Obes Surg       Date:  2019-06       Impact factor: 4.129

3.  Response to the Comment on: Effects of Laparoscopic Roux-en-Y Gastric Bypass for Type 2 Diabetes Mellitus: Comparison of BMI > 30 and < 30 kg/m2.

Authors:  Zhigang Ke; Weidong Tong
Journal:  Obes Surg       Date:  2018-03       Impact factor: 4.129

4.  Effect of Surgical Versus Medical Therapy on Diabetic Kidney Disease Over 5 Years in Severely Obese Adolescents With Type 2 Diabetes.

Authors:  Petter Bjornstad; Kara Hughan; Megan M Kelsey; Amy S Shah; Jane Lynch; Edward Nehus; Mark Mitsnefes; Todd Jenkins; Peixin Xu; Changchun Xie; Thomas Inge; Kristen Nadeau
Journal:  Diabetes Care       Date:  2019-11-04       Impact factor: 19.112

5.  Adolescent Bariatric Surgery: Effects of Socioeconomic, Demographic, and Hospital Characteristics on Cost, Length of Stay, and Type of Procedure Performed.

Authors:  Claire B Cummins; Omar Nunez Lopez; Byron D Hughes; Deepak Adhikari; Christopher A Guidry; Samantha Stubbs; Ravi S Radhakrishnan; Kanika A Bowen-Jallow
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

Review 6.  ASMBS pediatric metabolic and bariatric surgery guidelines, 2018.

Authors:  Janey S A Pratt; Allen Browne; Nancy T Browne; Matias Bruzoni; Megan Cohen; Ashish Desai; Thomas Inge; Bradley C Linden; Samer G Mattar; Marc Michalsky; David Podkameni; Kirk W Reichard; Fatima Cody Stanford; Meg H Zeller; Jeffrey Zitsman
Journal:  Surg Obes Relat Dis       Date:  2018-03-23       Impact factor: 4.734

7.  Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.

Authors:  Adnan Alsumali; Tewodros Eguale; Sigrid Bairdain; Mihail Samnaliev
Journal:  Obes Surg       Date:  2018-08       Impact factor: 4.129

Review 8.  Short- and long-term safety and efficacy of bariatric surgery for severely obese adolescents: a narrative review.

Authors:  Lauren A Sarno; Steven E Lipshultz; Carroll Harmon; Nestor F De La Cruz-Munoz; Preetha L Balakrishnan
Journal:  Pediatr Res       Date:  2019-08-11       Impact factor: 3.756

9.  Influence of Weight Loss on Obesity-Associated Complications After Metabolic and Bariatric Surgery in Adolescents.

Authors:  S Christopher Derderian; Luke Patten; Alexander M Kaizer; Jaime M Moore; Sarah Ogle; Todd M Jenkins; Marc P Michalsky; James E Mitchell; Petter Bjornstad; John B Dixon; Thomas H Inge
Journal:  Obesity (Silver Spring)       Date:  2020-12       Impact factor: 5.002

10.  Development and application of an ethical framework for pediatric metabolic and bariatric surgery evaluation.

Authors:  Jaime M Moore; Jacqueline J Glover; Brian M Jackson; Curtis R Coughlin; Megan M Kelsey; Thomas H Inge; Richard E Boles
Journal:  Surg Obes Relat Dis       Date:  2020-09-16       Impact factor: 4.734

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.